Takeda Neuchâtel opened its doors to 20 members of the Swiss Society of Industrial Pharmacists.
We got an insight into this biomanufacturing site, which manufactures 3 recombinant proteins to treat blood clotting disorders or deficiencies, as well as the new expansion to add aseptic filling capacity. The event closed with a nice opportunity to exchange with Takeda Operational staff.
With more than 700 employees, Takeda Neuchâtel is one of the ten largest employers in the Canton of Neuchâtel and one of the benchmark biopharmaceutical production sites in Switzerland. Active 24 hours a day, 7 days a week, the site employs a wide range of professionals trained in biotechnologies and their application in industrial production. Takeda Neuchâtel produces three drugs that treat two types of blood clotting disorders or deficiencies: - Factor VIII: It is a protein necessary for the blood coagulation chain. This protein is missing or deficient in patients with hemophilia A, the most common and well-known form of blood clotting disorders and deficiencies. - Factor VIII 'long lasting': This is a long-acting version of Factor VIII in the patient's body. - Von Willebrand Factor: It is a protein necessary for the blood clotting chain. This protein is missing or deficient in patients with Von Willebrand's disease, a rare and still underdiagnosed form of blood clotting disorders and deficiencies. Takeda Neuchâtel is the only biotechnology site in the world to produce the Von Willebrand Factor protein in the form of a recombinant product. It is a particularly complex and sensitive molecule. It took years of research and development to perfect its manufacturing process and to successfully produce it on an industrial scale. Von Willebrand Factor is the largest recombinant molecule produced at an industrial level. As such, Takeda Neuchâtel has a unique expertise in the world, developed over more than twenty years, which makes it a center of excellence recognized worldwide.
By Robin Steiner
on 02.05.2023 14:14